Requires the Director of the Department of Health and Human Services to seek to establish certain rates of reimbursement under Medicaid for certain devices to treat epilepsy. (BDR S-571)
If enacted, AB284 would establish significant modifications to the existing Medicaid provisions related to medical devices utilized for epilepsy treatment. By ensuring that reimbursement rates meet a specific threshold, the bill seeks to facilitate better access to necessary therapies for patients who may not afford them otherwise. The provision for separate reimbursement for implantation or repair services indicates a holistic approach to treating epilepsy through adequate healthcare funding mechanisms and infrastructure improvements within the health department.
Assembly Bill No. 284 (AB284), introduced by Assemblymember Brown-May, focuses on Medicaid reimbursement for vagus nerve stimulation therapy devices, which are used in the treatment of epilepsy. The bill mandates that the Director of the Department of Health and Human Services submit a request to the U.S. Secretary of Health and Human Services for reimbursement rates that are at least 82% of the acquisition costs for both the devices and any replacement parts necessary. This initiative aims to improve access to these specific medical devices for patients relying on Medicaid for their health coverage.
Noteworthy debates surrounding AB284 may arise around the financial implications of the proposed changes. There could be concerns regarding the appropriations required to support the new reimbursement structure, specifically the recommended expenditure of over $240,000 for the fiscal year 2026-2027. Additionally, stakeholders may express differing opinions regarding the balance between extending medical device coverage under Medicaid and the fiscal responsibilities this entails for the state budget.